Syncope recurrence can better be predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope

Background Head-up tilt testing is widely used in the evaluation of patients with suspected neurally mediated syncope. Although it remains unclear which patients require medical therapy to prevent recurrent syncope, most centres initiate empiric medical therapy in all patients in whom neurally media...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 1997-09, Vol.18 (9), p.1465-1469
Hauptverfasser: Grimm, W., Degenhardt, M., Hoffmann, J., Menz, V., Wirths, A., Maisch, B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Head-up tilt testing is widely used in the evaluation of patients with suspected neurally mediated syncope. Although it remains unclear which patients require medical therapy to prevent recurrent syncope, most centres initiate empiric medical therapy in all patients in whom neurally mediated syncope has been diagnosed. To determine the natural history of this condition, we followed 80 untreated patients. Methods All 80 study patients fulfilled the following inclusion criteria: (1) ≥1 syncope in the upright position, (2) absence of structural heart disease, (3) unremarkable work-up for other known causes of syncope. Thirty-nine patients had a history of one episode of syncope (group A) and 41≥2 episodes of syncope (group B). Head-up tilting was performed in all patients at 60° for a maximum of 45 min without medical provocation (‘Westminster Protocol’). Results Suspected neurally mediated syncope could be reproduced by tilt testing in four of 39 patients from group A vs 10 of 41 patients from group B (10% vs 24%, P=0·1). Independent of the result of head-up tilt testing, all patients were prospectively followed without medical therapy. During 23±8 months follow-up, syncope recurred in four of 39 group A patients vs 22 of 41 group B patients (10% vs 54%, P
ISSN:0195-668X
1522-9645
DOI:10.1093/oxfordjournals.eurheartj.a015473